#BEGIN_DRUGCARD DB01150

# AHFS_Codes:
08:12.06.08

# ATC_Codes:
J01DC10

# Absorption:
Oral bioavailability is approximately 95%.

# Biotransformation:
Cefprozil is eliminated primarily by the kidneys

# Brand_Mixtures:
Not Available

# Brand_Names:
Arzimol
Brisoral
Cronocef
Procef
Serozil

# CAS_Registry_Number:
92665-29-7

# ChEBI_ID:
3506

# Chemical_Formula:
C18H19N3O5S

# Chemical_IUPAC_Name:
(6R,7R)-7-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-8-oxo-3-(prop-1-en-1-yl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2163667

# Description:
Cefprozil is a cephalosporin antibiotic. It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections.

# Dosage_Forms:
Powder, for solution	Oral
Tablet	Oral

# Drug_Category:
Anti-Bacterial Agents
Cephalosporins

# Drug_Interactions:
Probenecid	Probenecid may increase the serum level of cefprozil.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.6

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
55 mg/L

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Cefprozil

# HET_ID:
Not Available

# Half_Life:
1.3 hours

# InChI_Identifier:
InChI=1S/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2+/t12-,13-,17-/m1/s1

# InChI_Key:
InChIKey=WDLWHQDACQUCJR-ZAMMOSSLSA-N

# Indication:
For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph

# KEGG_Compound_ID:
C06888

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1150

# Mechanism_Of_Action:
Cefprozil, like the penicillins, is a beta-lactam antibiotic. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefprozil interferes with an autolysin inhibitor.

# Melting_Point:
218-225 Â°C

# Molecular_Weight_Avg:
389.426

# Molecular_Weight_Mono:
389.104541423

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cef1077.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164746342

# Pharmacology:
Cefprozil, a semisynthetic, second-generation cephalosporin, is used to treat otitis media, soft-tissue infections, and respiratory tract infections.

# Predicted_LogP_Hydrophobicity:
0.94

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
1.49e-01 g/l

# Primary_Accession_No:
DB01150

# Protein_Binding:
36%

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/cefprozi.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00461

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]12SCC(C=CC)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Cefprozil anhydrous
Cefprozilo [INN-Spanish]
Cefprozilum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Single 5000 mg/kg oral doses of cefprozil caused no mortality or signs of toxicity in adult, weaning or neonatal rats, or adult mice. A single oral dose of 3000 mg/kg caused diarrhea and loss of appetite in cynomolgus monkeys, but no mortality.

# Update_Date:
2013-03-19 11:47:24 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Cefprozil

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11959556	Nagai K, Davies TA, Jacobs MR, Appelbaum PC: Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
X67873

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ponA

# Drug_Target_1_Gene_Sequence:
>2157 bp
ATGAACAAACCAACGATTCTGCGCCTAATCAAGTATCTGAGCATTAGCTTCTTAAGCTTG
GTTATCGCAGCCATTGTCTTAGGCGGAGGAGTTTTTTTCTACTACGTTAGCAAGGCTCCT
AGCCTATCCGAGAGTAAACTAGTTGCAACAACTTCTAGTAAAATCTACGACAATAAAAAT
CAACTCATTGCTGACTTGGGTTCTGAACGCCGCGTCAATGCCCAAGCTAATGATATTCCC
ACAGATTTGGTTAAGGCAATCGTTTCTATCGAAGACCATCGCTTCTTCGACCACAGGGGG
ATTGATACCATCCGTATCCTGGGAGCTTTCTTGCGCAATCTGCAAAGCAATTCCCTCCAA
GGTGGATCAACTCTCACTCAACAGTTGATTAAGTTGACTTACTTTTCAACTTCGACTTCC
GACCAGACTATTTCTCGTAAGGCTCAGGAAGCTTGGTTAGCGATTCAGTTAGAACAAAAA
GCAACCAAGCAAGAAATCTTGACCTACTATATAAATAAGGTCTACATGTCTAATGGGAAC
TATGGAATGCAGACAGCAGCTCAAAACTACTATGGTAAAGACCTCAATAATTTAAGTTTA
CCTCAGTTAGCCTTGCTGGCTGGAATGCCTCAGGCACCAAACCAATATGACCCCTATTCA
CATCCAGAAGCAGCCCAAGACCGCCGAAACTTGGTCTTATCTGAAATGAAAAATCAAGGC
TACATCTCTGCTGAACAGTATGAGAAAGCAGTCAATACACCAATTACTGATGGACTACAA
AGTCTCAAATCAGCAAGTAATTACCCTGCTTACATGGATAATTACCTCAAGGAAGTCATC
AATCAAGTTGAAGAAGAAACAGGCTATAACCTGCTCACAACTGGGATGGATGTCTACACA
AATGTAGACCAAGAAGCTCAAAAACATCTGTGGGATATTTACAATACAGACGAATACGTT
GCCTATCCAGACGATGAATTGCAAGTCGCTTCTACCATTGTTGATGTTTCTAACGGTAAA
GTCATTGCCCAGCTAGGAGCACGCCATCAGTCAAGTAATGTTTCCTTCGGAATTAACCAA
GCAGTAGAAACAAACCGCGACTGGGGATCAACTATGAAACCGATCACAGACTATGCTCCT
GCCTTGGAGTACGGTGTCTACGATTCAACTGCTACTATCGTTCACGATGAGCCCTATAAC
TACCCTGGGACAAATACCCCTGTTTATAACTGGGATAGGGGCTACTTTGGCAACATCACC
TTGCAATACGCCCTGCAACAATCGCGAAACGTCCCAGCCGTGGAAACTCTAAACAAGGTC
GGACTCAACCGCGCCAAGACTTTCCTAAATGGTCTCGGAATCGACTACCCAAGTATTCAC
TACTCAAATGCCATTTCAAGTAACACAACCGAATCAGACAAAAAATATGGAGCAAGTAGT
GAAAAGATGGCTGCTGCTTACGCTGCCTTTGCAAATGGTGGAACTTACTATAAACCAATG
TATATCCATAAAGTCGTCTTTAGTGATGGGAGTGAAAAAGAGTTCTCTAATGTCGGAACT
CGTGCCATGAAGGAAACGACAGCCTATATGATGACCGAAATGATGAAAACAGTCTTGACT
TATGGAACTGGACGAAATGCCTATCTTGCTTGGCTCCCTCAGGCTGGTAAAACAGGAACC
TCTAACTATACAGATGAGGAAATTGAAAACCACATCAAGACCTCTCAATTTGTAGCACCT
GATGAACTATTTGCTGGCTATACGCGTAAATATTCAATGGCTGTATGGACAGGCTATTCT
AACCGTCTGACACCACTTGTAGGCAATGGCCTTACGGTCGCTGCCAAAGTTTACCGCTCT
ATGATGACCTACCTGTCTGAAGGAAGCAATCCAGAGGATTGGAATATACCAGAGGGGCTC
TACAGAAATGGAGAATTCGTATTTAAAAATGGTGCTCGTTCTACGTGGAGCTCACCTGCT
CCACAACAACCCCCATCAACTGAAAGTTCAAGCTCATCATCAGATAGTTCAACTTCACAG
TCTAGCTCAACCACTCCAAGCACAAATAATAGTACGACTACCAATCCTAACAATAATACG
CAACAATCAAATACAACCCCTGATCAACAAAATCAGAATCCTCAACCAGCACAACCA

# Drug_Target_1_General_Function:
Involved in catalytic activity

# Drug_Target_1_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
1396576	Martin C, Sibold C, Hakenbeck R: Relatedness of penicillin-binding protein 1a genes from different clones of penicillin-resistant Streptococcus pneumoniae isolated in South Africa and Spain. EMBO J. 1992 Nov;11(11):3831-6.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5805

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
79759

# Drug_Target_1_Name:
Penicillin-binding protein 1A

# Drug_Target_1_Number_of_Residues:
719

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00905	Transpeptidase
PF00912	Transgly

# Drug_Target_1_Protein_Sequence:
>Penicillin-binding protein 1A
MNKPTILRLIKYLSISFLSLVIAAIVLGGGVFFYYVSKAPSLSESKLVATTSSKIYDNKN
QLIADLGSERRVNAQANDIPTDLVKAIVSIEDHRFFDHRGIDTIRILGAFLRNLQSNSLQ
GGSTLTQQLIKLTYFSTSTSDQTISRKAQEAWLAIQLEQKATKQEILTYYINKVYMSNGN
YGMQTAAQNYYGKDLNNLSLPQLALLAGMPQAPNQYDPYSHPEAAQDRRNLVLSEMKNQG
YISAEQYEKAVNTPITDGLQSLKSASNYPAYMDNYLKEVINQVEEETGYNLLTTGMDVYT
NVDQEAQKHLWDIYNTDEYVAYPDDELQVASTIVDVSNGKVIAQLGARHQSSNVSFGINQ
AVETNRDWGSTMKPITDYAPALEYGVYDSTATIVHDEPYNYPGTNTPVYNWDRGYFGNIT
LQYALQQSRNVPAVETLNKVGLNRAKTFLNGLGIDYPSIHYSNAISSNTTESDKKYGASS
EKMAAAYAAFANGGTYYKPMYIHKVVFSDGSEKEFSNVGTRAMKETTAYMMTDMMKTVLT
YGTGRNAYLAWLPQAGKTGTSNYTDEEIENHIKTSQFVAPDELFAGYTRKYSMAVWTGYS
NRLTPLVGNGLTVAAKVYRSMMTYLSEGSNPEDWNIPEGLYRNGEFVFKNGARSTWNSPA
PQQPPSTESSSSSSDSSTSQSSSTTPSTNNSTTTNPNNNTQQSNTTPDQQNQNPQPAQP

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Cell wall formation

# Drug_Target_1_SwissProt_ID:
Q04707

# Drug_Target_1_SwissProt_Name:
PBPA_STRPN

# Drug_Target_1_Synonyms:
PBP-1A

# Drug_Target_1_Theoretical_pI:
5.29

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cell membrane

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11959556	Nagai K, Davies TA, Jacobs MR, Appelbaum PC: Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
AE005672

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
pbpX

# Drug_Target_2_Gene_Sequence:
>2253 bp
ATGAAGTGGACAAAAAGAGTAATCCGTTATGCGACCAAAAATCGGAAATCGCCGGCTGAA
AACAGACGCAGAGTTGGAAAAAGTCTGAGTTTATTATCTGTCTTTGTTTTTGCCATTTTT
TTAGTCAATTTTGCGGTCATTATTGGGACAGGCACTCGCTTTGGAACAGATTTAGCGAAG
GAAGCTAAGAAGGTTCATCAAACCACCCGTACAGTTCCTGCCAAACGTGGGACTATTTAT
GACCGAAATGGAGTCCCGATTGCTGAGGATGCAACCTCCTATAATGTCTATGCGGTCATT
GATGAGAACTATAAGTCAGCAACGGGTAAGATTCTTTACGTAGAAAAAACACAATTTAAC
AAGGTTGCAGAGGTCTTTCATAAGTATCTGGACATGGAAGAATCCTATGTAAGAGAGCAA
CTCTCGCAACCTAATCTCAAGCAAGTTTCCTTTGGAGCAAAGGGAAATGGGATTACCTAT
GCCAATATGATGTCTATCAAAAAAGAATTGGAAGCTGCAGAGGTCAAGGGGATTGATTTT
ACAACCAGTCCCAATCGTAGTTACCCAAACGGACAATTTGCTTCTAGTTTTATCGGTCTA
GCTCAGCTCCATGAAAATGAAGATGGAAGCAAGAGCTTGCTGGGAACCTCTGGAATGGAG
AGTTCCTTGAACAGTATTCTTGCAGGGACAGACGGCATTATTACCTATGAAAAGGATCGT
CTGGGTAATATTGTACCCGGAACAGAACAAGTTTCCCAACGAACGATGGACGGTAAGGAT
GTTTATACAACCATTTCCAGCCCCCTCCAGTCCTTTATGGAAACCCAGATGGATGCTTTT
CAAGAGAAGGTAAAAGGAAAGTACATGACAGCGACTTTGGTCAGTGCTAAAACAGGGGAA
ATTCTGGCAACAACGCAACGACCGACCTTTGATGCAGATACAAAAGAAGGCATTACAGAG
GACTTTGTTTGGCGTGATATCCTTTACCAAAGTAACTATGAGCCAGGTTCCACTATGAAA
GTGATGATGTTGGCTGCTGCTATTGATAATAATACCTTTCCAGGAGGAGAAGTCTTTAAT
AGTAGTGAGTTAAAAATTGCAGATGCCACGATTCGAGATTGGGACGTTAATGAAGGATTG
ACTGGTGGCAGAACGATGACTTTTTCTCAAGGTTTTGCACACTCAAGTAACGTTGGGATG
ACCCTCCTTGAGCAAAAGATGGGAGATGCTACCTGGCTTGATTATCTTAATCGTTTTAAA
TTTGGAGTTCCGACCCGTTTCGGTTTGACGGATGAGTATGCTGGTCAGCTTCCTGCGGAT
AATATTGTCAACATTGCGCAAAGCTCATTTGGACAAGGGATTTCAGTGACCCAGACGCAA
ATGATTCGTGCCTTTACAGCTATTGCTAATGACGGTGTCATGCTGGAGCCTAAATTTATT
AGTGCCATTTATGATCCAAATGATCAAACTGCTCGGAAATCTCAAAAAGAAATTGTGGGA
AATCCTGTTTCTAAAGATGCAGCTAGTCTAACTCGGACTAACATGGTTTTGGTAGGGACG
GATCCGGTTTATGGAACCATGTATAACCACAGCACAGGCAAGCCAACTGTAACTGTTCCT
GGGCAAAATGTAGCCCTCAAGTCTGGTACGGCTCAGATTGCTGACGAGAAAAATGGTGGT
TATCTAGTCGGGTTAACCGACTATATTTTCTCGGCTGTATCGATGAGTCCGGCTGAAAAT
CCTGATTTTATCTTGTATGTGACGGTCCAACAACCTGAACATTATTCAGGTATTCAGTTG
GGAGAATTTGCCAATCCTATCTTGGAGCGGGCTTCAGCTATGAAAGACTCTCTCAATCTT
CAAACAACAGCTAAGGCTTTAGAGCAAGTAAGTCAACAAAGTCCTTATCCTATGCCTAGT
GTCAAGGATATTTCACCTGGTGATTTAGCAGAAGAATTGCGTCGCAATCTTGTACAACCC
ATCGTTGTGGGAACAGGAACGAAGATTAAAAACAGTTCTGCTGAAGAAGGGAAGAATCTT
GCCCCGAACCAGCAAGTCCTTATCTTATCTGATAAAGCAGAGGAGGTTCCAGATATGTAT
GGTTGGACAAAGGAGACTGCTGAGACCCTTGCTAAGTGGCTCAATATAGAACTTGAATTT
CAAGGTTCGGGCTCTACTGTGCAGAAGCAAGATGTTCGTGCTAACACAGCTATCAAGGAC
ATTAAAAAAATTACATTAACTTTAGGAGACTAA

# Drug_Target_2_General_Function:
Involved in penicillin binding

# Drug_Target_2_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
8605631	Pares S, Mouz N, Petillot Y, Hakenbeck R, Dideberg O: X-ray structure of Streptococcus pneumoniae PBP2x, a primary penicillin target enzyme. Nat Struct Biol. 1996 Mar;3(3):284-9.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
4154

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
82314

# Drug_Target_2_Name:
Penicillin-binding protein 2x

# Drug_Target_2_Number_of_Residues:
750

# Drug_Target_2_PDB_ID:
1QMF

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer
PF03793	PASTA

# Drug_Target_2_Protein_Sequence:
>Penicillin-binding protein 2x
MKWTKRVIRYATKNRKSPAENRRRVGKSLSLLSVFVFAIFLVNFAVIIGTGTRFGTDLAK
EAKKVHQTTRTVPAKRGTIYDRNGVPIAEDATSYNVYAVIDENYKSATGKILYVEKTQFN
KVAEVFHKYLDMEESYVREQLSQPNLKQVSFGAKGNGITYANMMSIKKELEAAEVKGIDF
TTSPNRSYPNGQFASSFIGLAQLHENEDGSKSLLGTSGMESSLNSILAGTDGIITYEKDR
LGNIVPGTEQVSQRTMDGKDVYTTISSPLQSFMETQMDAFQEKVKGKYMTATLVSAKTGE
ILATTQRPTFDADTKEGITEDFVWRDILYQSNYEPGSTMKVMMLAAAIDNNTFPGGEVFN
SSELKIADATIRDWDVNEGLTGGRTMTFSQGFAHSSNVGMTLLEQKMGDATWLDYLNRFK
FGVPTRFGLTDEYAGQLPADNIVNIAQSSFGQGISVTQTQMIRAFTAIANDGVMLEPKFI
SAIYDPNDQTARKSQKEIVGNPVSKDAASLTRTNMVLVGTDPVYGTMYNHSTGKPTVTVP
GQNVALKSGTAQIADEKNGGYLVGLTDYIFSAVSMSPAENPDFILYVTVQQPEHYSGIQL
GEFANPILERASAMKDSLNLQTTAKALEQVSQQSPYPMPSVKDISPGDLAEELRRNLVQP
IVVGTGTKIKNSSAEEGKNLAPNQQVLILSDKAEEVPDMYGWTKETAETLAKWLNIELEF
QGSGSTVQKQDVRANTAIKDIKKITLTLGD

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Penicillin-binding proteins (PBPs) function in the late steps of murein biosynthesis. Beta-lactams inactivate the PBPs by acylating an essential serine residue in the active site of these proteins

# Drug_Target_2_SwissProt_ID:
P14677

# Drug_Target_2_SwissProt_Name:
PBPX_STRPN

# Drug_Target_2_Synonyms:
PBP-2x
PBP2x

# Drug_Target_2_Theoretical_pI:
5.53

# Drug_Target_2_Transmembrane_Regions:
29-49

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
11959556	Nagai K, Davies TA, Jacobs MR, Appelbaum PC: Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
AE005672

# Drug_Target_3_GenBank_ID_Protein:
14973165

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
penA

# Drug_Target_3_Gene_Sequence:
>2043 bp
CTAATTCATTGGATGGTATTTTTGATACAGATTGATAATGTCACGCGCAATGGAAGGTCC
TACACCATTTGTTAGATTGGTATTATGAGGAAAGACCACTGCGACAGCGATTTGGGGATT
ATCAGATGGGGCATAGGCCACCGCATTGGTATTGGTTGCTTGCTGACCATCTGCCACATA
GCTTTCGGCTGTACCTGTTTTTCCGCTAATGGATACCAAGGCACCATTTGAAAAGGCACG
TCCAGTTGTCAATCCACTAGTACCATGGGCAACCTGATAAAAACCTTGGTGCAAGATGCT
CATATCGGAGTCGGATATATTGACCTTATTCATCTCTGTCGGTTGCAGTTGCTGAATCAA
GTCACCCAGTCCTCCCTTATCATTATTACCATAAATGCCTTCAACAATACGAGGAGCCAC
ACGAACACCATTATTTGCAATAGTTGCTACATACTGAGCCAACTGCATCGGCGTATAGTT
ATCAAACTGCCCAAAGGCATTAGTAATGTAATTAGCAAAGCTATACTCTTTGGGAACAAA
TCCAGTAGATTCATCTGGTAGGTCAATTCCTGTCGCAGTACCCAAGCCATATTCGCCAAA
GGTTGAACGCAGTTTCTCCATAGCAGACTCTAGATTGCTGGTGCCGACAAACATATTGGG
TTGATAGGTTTGCCCCATAAGACCTAAGGCTGTTTGGACCATATAGGTATTTGATGAATA
CTCCAGAGCTTGGACCGCTGTGATAGGGAATGAACCGTAAGCCTGAGTATACCAAGAATT
GATGGGAGCTGAACCTTGGAAGACAATGGACTGGTCTGTCAAGGTCTGGTTTCCTGACAA
GACTCCATTTTCCCAACCTGAGCTGATGGTCGCCGCCTTGACAACCGAACCTGGAACAAA
GACATTGGTTACCGTTCCCAAGGAATCAGGCGTCAACTCTCCCGTTTTCAAGTCATGTTT
AATCCCTGACATAGACAAAACCGCACCTGTTTTTGGGTTAAGGGCGACTGCATAGACACC
TTCAGAATACTTGGCTCCACCATTTTCTAGCTCAGAATTGAAATAACTTTTCAGTAAAGC
ATCCACGCTATCTTGGAAAGCCAAATCAATGGTCAGTTTGATATTGTTTCCCTTACTACC
TTCCTCAATTGTATCCACGCTTTCCATATTGCCATATTTATCCAGATGGATTTCTTTTAC
CGAGCGTTTTCCTTGTAAGGTCTCTTCATATTGCTTTTCCAAATAGGAGGTTCCTACACG
GTCATTTAGAGAATAGCCTTTTTTAAGATAGGCTTCTGCTTCTTCCGCTGGGAGACCAGC
TTTTTCACTGGATACACTCCCAACTATAGAAGAAAGGGAAGTTTCCAAAACCTTTCTATC
CCAAGAAGTAGAAATACTAATGCCAGGCATCTCCTTTGAAATAGAGGCAATAACAGCCAC
CTGAGAATCATTTAGAGGATCTGTCGCAATGGTTCCTGTCGCAAAGTTTCCAACAGCATT
TAACTGACTAAAAAGATAGATTTCTTTCTTTTCATCCTCTGTATAGTTTAGTTGACTCGT
TTGTACACTATCGACCGCATTGTTATACAGTTCTGATTCGGATAGACGATTGCCATCTGA
ATCCAAGCGTTTCTCACTTGGGAGAGCTTCCACTATTTTTTTATAGATTTCAGGATCAGC
CAAATAGTAATCCGCCAGCTGGCGTTCTGTCAAATTTGGAGAACTGATGCTCACATAAGT
CAGTAACTTTTTAGCTGTTTCTTTTAAGTCTGTAGCCGTCATTTTATTGCTACGCGTAAA
GGAAACAACCTGCTTTAACGTATTTTCTACCAAAGGTTTTCCACTAGCATCATAAATTTC
CCCACGGGCTGAACTGCTTGTAATCTTGGTCTGACTAGCTGAAGCTAGCTTTTTTTCGTA
AAAATCCTTGTTCAAAACCTGCATATACAACAAACGACCAATAATGGTCATAAAGAGTAA
AATGACGATTGAAAACAATAAATTAAGCCGAATCGGAATCGAATGGCTGTTAAATTTTCT
CAT

# Drug_Target_3_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_3_General_References:
11463916	Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, Peterson S, Heidelberg J, DeBoy RT, Haft DH, Dodson RJ, Durkin AS, Gwinn M, Kolonay JF, Nelson WC, Peterson JD, Umayam LA, White O, Salzberg SL, Lewis MR, Radune D, Holtzapple E, Khouri H, Wolf AM, Utterback TR, Hansen CL, McDonald LA, Feldblyum TV, Angiuoli S, Dickinson T, Hickey EK, Holt IE, Loftus BJ, Yang F, Smith HO, Venter JC, Dougherty BA, Morrison DA, Hollingshead SK, Fraser CM: Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science. 2001 Jul 20;293(5529):498-506.
2654541	Dowson CG, Hutchison A, Spratt BG: Extensive re-modelling of the transpeptidase domain of penicillin-binding protein 2B of a penicillin-resistant South African isolate of Streptococcus pneumoniae. Mol Microbiol. 1989 Jan;3(1):95-102.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
159

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
73874

# Drug_Target_3_Name:
Penicillin-binding protein 2B

# Drug_Target_3_Number_of_Residues:
680

# Drug_Target_3_PDB_ID:
Not Available

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00905	Transpeptidase
PF03717	PBP_dimer

# Drug_Target_3_Protein_Sequence:
>Penicillin-binding protein 2B
MRKFNSHSIPIRLNLLFSIVILLFMTIIGRLLYMQVLNKDFYEKKLASASQTKITSSSAR
GEIYDASGKPLVENTLKQVVSFTRSNKMTATDLKETAKKLLTYVSISSPNLTERQLADYY
LADPEIYKKIVEALPSEKRLDSDGNRLSESELYNNAVDSVQTSQLNYTEDEKKEIYLFSQ
LNAVGNFATGTIATDPLNDSQVAVIASISKEMPGISISTSWDRKVLETSLSSIVGSVSSE
KAGLPAEEAEAYLKKGYSLNDRVGTSYLEKQYEETLQGKRSVKEIHLDKYGNMESVDTIE
EGSKGNNIKLTIDLAFQDSVDALLKSYFNSELENGGAKYSEGVYAVALNPKTGAVLSMSG
IKHDLKTGELTPDSLGTVTNVFVPGSVVKAATISSGWENGVLSGNQTLTDQSIVFQGSAP
INSWYTQAYGSFPITAVQALEYSSNTYMVQTALGLMGQTYQPNMFVGTSNLESAMEKLRS
TFGEYGLGTATGIDLPDESTGFVPKEYSFANYITNAFGQFDNYTPMQLAQYVATIANNGV
RVAPRIVEGIYGNNDKGGLGDLIQQLQPTEMNKVNISDSDMSILHQGFYQVAHGTSGLTT
GRAFSNGALVSISGKTGTAESYVADGQQATNTNAVAYAPSDNPQIAVAVVFPHNTNLTNG
VGPSIARDIINLYQKYHPMN

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
P0A3M5

# Drug_Target_3_SwissProt_Name:
PBP2_STRPN

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
4.85

# Drug_Target_3_Transmembrane_Regions:
13-32

#END_DRUGCARD DB01150
